CAM
STLN

Cresset Asset Management’s Starling Oncology STLN Stock Holding History

Cresset Asset Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,300
Closed -$5.98K – 2190
2024
Q3 		$5.98K Hold
18,300
– – ﹤0.01% 2176
2024
Q2 		$8.42K Buy
+18,300
New +$15.6K ﹤0.01% 2087

Other funds holding STLN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FL
FreeGulliver LLC New Orleans, Louisiana $284M AUM 24.22% 1-Year Est. Return
QFA
Quattro Financial Advisors The Woodlands, Texas $468M AUM 13.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cresset Asset Management's STLN Position: Q4 2024 in Review

Cresset Asset Management sold out of Starling Oncology (STLN) in Q4 2024, closing a stake of 18,300 shares — an estimated $5.98K sold.

Cresset Asset Management first reported a position in STLN in Q2 2024 and held it in 2 quarters. The position peaked at $8.42K in Q2 2024. 31 funds tracked by Wall St. Rank hold STLN as of Q4 2024.

  • Cresset Asset Management reported no remaining Starling Oncology position as of Q4 2024 after selling out during the quarter.
  • Cresset Asset Management sold 18,300 Starling Oncology shares in Q4 2024, an estimated $5.98K.
  • Cresset Asset Management first reported a position in Starling Oncology in Q2 2024 and held it in 2 quarters.
  • Cresset Asset Management's Starling Oncology position peaked at $8.42K in Q2 2024.
  • 31 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.